Buruli ulcer: advances in understanding Mycobacterium ulcerans infection

DS Walsh, F Portaels, WM Meyers

    Research output: Contribution to journalA1: Web of Science-articlepeer-review


    Buruli ulcer (BU), caused by the environmental organism Mycobacterium ulcerans and characterized by necrotizing skin and bone lesions, poses important public health issues as the third most common mycobacterial infection in humans. Pathogenesis of M ulcerans is mediated by mycolactone, a necrotizing immunosuppressive toxin. First-line therapy for BU is rifampin plus streptomycin, sometimes with surgery. New insights into the pathogenesis of BU should improve control strategies.
    Original languageEnglish
    JournalDermatologic Clinics
    Issue number1
    Pages (from-to)1-8
    Publication statusPublished - 2011


    • B780-tropical-medicine
    • Bacterial diseases
    • Buruli ulcer
    • Mycobacterium ulcerans
    • Pathogenesis
    • Mycolactone toxin
    • First-line drugs
    • Rifampin
    • Streptomycin
    • Surgery


    Dive into the research topics of 'Buruli ulcer: advances in understanding Mycobacterium ulcerans infection'. Together they form a unique fingerprint.

    Cite this